Asuragen
在场
Asuragen 的所有者是 Bio-Techne.
是其中之一......
Bio-Techne 是一家在股票代码 TECH (US) 下上市的公司。
他们在：
涉及Bio-Techne的并购和融资。
- Bio-Techne has announced the acquisition of Lunaphore (公布2023六月23号).
高管
查看带有其 8 名主要高管的组织结构图
Asuragen 搜索最多的简介
- David Sargent, Director
- Deval Lashkari, Director
- Matt Winkler, Chairman of the Board and Chief Scientific Officer
高管在Bio-Techne变化
- Matthew McmanusMatthew Mcmanus 将于20242月1作为 President, Diagnostics and Genomics Segment 加入公司 (新闻发布的2024一月7号).
- Kim Kelderman 曾任 President, Diagnostics and Genomics, 将于 20242月1 升职为 Director, President and Chief Executive Officer (新闻发布的2023十月19号).
创建提醒
跟踪 Asuragen 的高管变动
生物技术
Bio-Techne 拥有 2,282 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Asuragen 的最新新闻稿
- LinkedIn Login, Sign in | LinkedIn
- BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA - Asuragen
- https://twitter.com/home?status=BIO-TECHNE%20RECEIVES%20EUROPEAN%20IVDR%20CERTIFICATION%20FOR%20DIAGNOSTIC%20TEST%20TO%20MONITOR%20CHRONIC%20MYELOID%20LEUKEMIA%20https%3A%2F%2Fasuragen.com%2Fnews-list%2Fbio-techne-receives-european-ivdr-certification-for-diagnostic-test-to-monitor-chronic-myeloid-leukemia%2F
- BIO-TECHNE AND OXFORD NANOPORE TECHNOLOGIES PARTNER TO BRING INNOVATIVE REPRODUCTIVE HEALTH AND CARRIER SCREENING SOLUTIONS TO THE MARKET - Asuragen
- LinkedIn Login, Sign in | LinkedIn
- Log in or sign up to view
- LinkedIn Login, Sign in | LinkedIn
- ASURAGEN TO SHOWCASE INNOVATIVE DIAGNOSTIC LAB SOLUTIONS AT AMP 2022 CONFERENCE - Asuragen
- News - Asuragen
- View more press releases Close
通过电子邮件
